Annoroad's Novel Coronavirus nucleic acid detection kit was granted access to the EU CE to help the global pandemic prevention and control

After more than three months of all-out fight against the COVID-19, the epidemic situation in China continues to improve, but the situation overseas is not optimistic. According to the latest WHO report, the cumulative number of confirmed cases overseas has reached nearly 400,000 so far.

To alleviate the overseas pandemic, the Novel Coronavirus (2019-nCoV) nucleic acid detection kit (immunofluorescence and RT-PCR) developed by Annoroad has recently been granted access to EU CE. This kit meets the requirements of the EU directives on medical devices and meets the access conditions of the EU market. At present, the kit has been officially put into production and entered the global market, contributing to the global fight against COVID-19.

CE Certificate of Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit (Fluorescence & RT-PCR)


Annoroad's Novel Coronavirus nucleic acid detection kit has been granted access to EU CE, which fully proves that Annoroad possesses the technology and strength required for epidemic prevention and control. Faced with the grim situation of the COVID-19 pandemic worldwide, WHO declared COVID-19 a global pandemic and called on countries to take comprehensive measures to do everything possible to contain it. The Novel Coronavirus detection kit developed by Annoroad will also help the COVID-19 epidemic prevention and control worldwide.


Nucleic acid testing of Novel Coronavirus is one of the important means to diagnose COVID-19 infection. After the outbreak of COVID-19, Annoroad team made a prompt response and quickly invested in research and development. After several rounds of rigorous optimization and experimental verification, the Novel Coronavirus nucleic acid detection kit was successfully developed. This kit, based on Taq-man multiple fluorescent RT-PCR technology, targets key genes in the Novel Coronavirus genome, using the highly specific ORF1ab target released by the Chinese Center for Disease Control and Prevention and the highly sensitive E gene released by the WHO for dual-target simultaneous detection, so as to make up for the current problem of false negative diagnosis and reduce the risk of missing detection caused by virus mutations. In addition, it can detect at least 5 copies of viral gene signals, has high precision and sensitivity, and overcomes the defect of probe fluorescence imbalance. Moreover, it can be adapted to a variety of qPCR detection platforms to meet the detection needs of various medical institutions.


Copyright © Annoroad Gene Technology 京ICP备12029022号-1